Cogent Submits NDA for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Should l Buy COGT?
Source: Globenewswire
- NDA Submission: Cogent Biosciences has submitted its New Drug Application for bezuclastinib targeting NonAdvanced Systemic Mastocytosis to the FDA, based on positive clinical data from the SUMMIT pivotal trial, marking a significant advancement in the precision therapy landscape.
- Clinical Trial Results: The SUMMIT trial demonstrated statistical significance across all primary and key secondary endpoints, with updated data through 48 weeks showing sustained symptomatic improvement, indicating the potential for long-term clinical benefits of the drug.
- Breakthrough Therapy Designation: Bezuclastinib received Breakthrough Therapy Designation from the FDA in October 2025, reflecting its potential to address significant unmet medical needs and enhancing the company's competitive position in the market.
- Future Plans: Cogent plans to submit two additional NDAs for bezuclastinib in Gastrointestinal Stromal Tumors and Advanced Systemic Mastocytosis in the first half of 2026, based on strong results from the PEAK and APEX clinical trials, showcasing the company's ongoing development potential in oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COGT
Wall Street analysts forecast COGT stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 37.080
Low
34.00
Averages
50.36
High
67.00
Current: 37.080
Low
34.00
Averages
50.36
High
67.00
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bezuclastinib Shows Significant Clinical Trial Results
- Significant Efficacy Improvement: Bezuclastinib treatment resulted in a mean TSS reduction of 32.0 points at 48 weeks, reflecting a 56% relative improvement from baseline, indicating its potential efficacy in Non-Advanced Systemic Mastocytosis patients.
- Widespread Symptom Improvement: 99% of patients achieved over a 50% reduction in serum tryptase levels at 48 weeks, with 83% normalizing, highlighting Bezuclastinib's significant impact on enhancing patient quality of life.
- Bone Density Enhancement: Patients treated with Bezuclastinib exhibited clinically meaningful improvements in bone mineral density at 24 weeks, further supporting its potential as a disease-modifying agent, particularly in high unmet need populations.
- Favorable Safety Profile: Bezuclastinib demonstrated a good safety and tolerability profile, supporting its potential for chronic use in Non-Advanced Systemic Mastocytosis patients, positioning it as a likely preferred standard of care.
See More
COGENT SECURITY SECURES FUNDING LED BY BAIN CAPITAL VENTURES, WITH CONTRIBUTIONS FROM GREYLOCK PARTNERS AND DEFINITION
Funding Announcement: COGENT SECURITY has secured funding led by Bain Capital Ventures, indicating strong investor confidence in the company's potential.
Investor Participation: The funding round also saw participation from existing investor Greylock Partners, highlighting ongoing support from established venture capital firms.
See More
Rock Springs Capital Reduces Stake in Cogent Biosciences
- Stake Reduction Details: Rock Springs Capital Management disclosed a reduction of 159,278 shares in Cogent Biosciences during Q4 2026, with an estimated transaction value of $4.48 million, indicating that despite the reduction, confidence in the company remains intact.
- Market Performance Analysis: As of February 16, 2026, Cogent's share price stood at $36.53, reflecting a remarkable 346.6% increase over the past year, significantly outperforming the S&P 500 by 334.8 percentage points, showcasing its strong position in the biotech sector.
- Financial Overview: Cogent boasts a market capitalization of $5.82 billion, and despite a net loss of $294.37 million over the past twelve months, it holds approximately $901 million in cash and marketable securities, ensuring operational funding through 2028.
- Future Growth Potential: Cogent is advancing multiple new drug applications, including bezuclastinib for non-advanced systemic mastocytosis, with an APEX NDA submission expected in the first half of 2026, demonstrating its ongoing innovation in oncology.
See More
First Turn Management Acquires New Position in Cogent Biosciences
- New Investment Disclosure: On February 13, 2026, First Turn Management disclosed the acquisition of 824,283 shares of Cogent Biosciences for $29.28 million, indicating strong confidence in the company's future prospects.
- Significant Ownership: This new position represents 3.35% of First Turn Management's reportable U.S. equity assets as of December 31, 2025, highlighting its strategic importance within the portfolio.
- Outstanding Market Performance: As of February 13, 2026, Cogent's shares were priced at $36.53, reflecting a remarkable 346.6% increase over the past year, significantly outperforming the S&P 500 by 334.8 percentage points, showcasing its robust market performance.
- Strong Financial Position: Cogent enters 2026 with approximately $901 million in cash and marketable securities, providing a runway into 2028, although it reported a net loss of $328.9 million for 2025, which is typical for late-stage biotech firms, underscoring execution risks.
See More
Fairmount Funds Management Sells 3.5 Million Shares of Cogent
- Sale Overview: On January 22, 2026, Fairmount Funds Management LLC indirectly sold 3.5 million shares of Cogent at $36.40 per share, generating approximately $127.4 million in transaction value, which represented 38.87% of its total indirect holdings, reducing its stake from 9,003,418 to 5,503,418 shares.
- Stock Surge Context: Cogent's stock skyrocketed over 342% in 2025, and this significant share sale has sparked speculation about management taking profits, although Fairmount's exact motives remain unclear; nonetheless, the over $120 million gain from this transaction is substantial.
- Holding Structure Analysis: Despite the large sale of common shares, Fairmount still holds approximately 67,414 units of Series A Convertible Preferred Stock, which could convert to about 16.85 million common shares, but due to a 9.9% ownership limit, they would need to sell some common shares first to facilitate this conversion.
- Investment Strategy and Market Performance: Fairmount Funds focuses heavily on biotech investments, with Cogent being a key part of its portfolio, showcasing potential in targeted therapies for rare diseases, and combined with its strong market performance, it may present long-term profit opportunities for investors.
See More
Fairmount Funds Sells 3.5 Million Shares of Cogent Biosciences
- Transaction Overview: On January 22, 2026, Fairmount Funds Management LLC indirectly sold 3.5 million shares of Cogent Biosciences for approximately $127.4 million, highlighting its investment strategy in the biotech sector.
- Change in Holdings: This transaction reduced Fairmount's indirect holdings by 38.87%, leaving 5,503,418 shares, which may indicate a potential shift in confidence regarding Cogent's future prospects.
- Market Context Analysis: At the time of the sale, Cogent's shares were priced at $36.40, lower than the closing price of $39.53 that day, suggesting a cautious market sentiment that could impact investor confidence.
- Investor Implications: Although Fairmount still holds about 67,414 units of Series A Convertible Preferred Stock, which could convert to approximately 16.85 million common shares, the 9.9% ownership limit will restrict future sales, affecting liquidity management.
See More
Bezuclastinib Shows Significant Clinical Trial Results
- Significant Efficacy Improvement: Bezuclastinib treatment resulted in a mean TSS reduction of 32.0 points at 48 weeks, reflecting a 56% relative improvement from baseline, indicating its potential efficacy in Non-Advanced Systemic Mastocytosis patients.
- Widespread Symptom Improvement: 99% of patients achieved over a 50% reduction in serum tryptase levels at 48 weeks, with 83% normalizing, highlighting Bezuclastinib's significant impact on enhancing patient quality of life.
- Bone Density Enhancement: Patients treated with Bezuclastinib exhibited clinically meaningful improvements in bone mineral density at 24 weeks, further supporting its potential as a disease-modifying agent, particularly in high unmet need populations.
- Favorable Safety Profile: Bezuclastinib demonstrated a good safety and tolerability profile, supporting its potential for chronic use in Non-Advanced Systemic Mastocytosis patients, positioning it as a likely preferred standard of care.
See More
COGENT SECURITY SECURES FUNDING LED BY BAIN CAPITAL VENTURES, WITH CONTRIBUTIONS FROM GREYLOCK PARTNERS AND DEFINITION
Funding Announcement: COGENT SECURITY has secured funding led by Bain Capital Ventures, indicating strong investor confidence in the company's potential.
Investor Participation: The funding round also saw participation from existing investor Greylock Partners, highlighting ongoing support from established venture capital firms.
See More
Rock Springs Capital Reduces Stake in Cogent Biosciences
- Stake Reduction Details: Rock Springs Capital Management disclosed a reduction of 159,278 shares in Cogent Biosciences during Q4 2026, with an estimated transaction value of $4.48 million, indicating that despite the reduction, confidence in the company remains intact.
- Market Performance Analysis: As of February 16, 2026, Cogent's share price stood at $36.53, reflecting a remarkable 346.6% increase over the past year, significantly outperforming the S&P 500 by 334.8 percentage points, showcasing its strong position in the biotech sector.
- Financial Overview: Cogent boasts a market capitalization of $5.82 billion, and despite a net loss of $294.37 million over the past twelve months, it holds approximately $901 million in cash and marketable securities, ensuring operational funding through 2028.
- Future Growth Potential: Cogent is advancing multiple new drug applications, including bezuclastinib for non-advanced systemic mastocytosis, with an APEX NDA submission expected in the first half of 2026, demonstrating its ongoing innovation in oncology.
See More
First Turn Management Acquires New Position in Cogent Biosciences
- New Investment Disclosure: On February 13, 2026, First Turn Management disclosed the acquisition of 824,283 shares of Cogent Biosciences for $29.28 million, indicating strong confidence in the company's future prospects.
- Significant Ownership: This new position represents 3.35% of First Turn Management's reportable U.S. equity assets as of December 31, 2025, highlighting its strategic importance within the portfolio.
- Outstanding Market Performance: As of February 13, 2026, Cogent's shares were priced at $36.53, reflecting a remarkable 346.6% increase over the past year, significantly outperforming the S&P 500 by 334.8 percentage points, showcasing its robust market performance.
- Strong Financial Position: Cogent enters 2026 with approximately $901 million in cash and marketable securities, providing a runway into 2028, although it reported a net loss of $328.9 million for 2025, which is typical for late-stage biotech firms, underscoring execution risks.
See More
Fairmount Funds Management Sells 3.5 Million Shares of Cogent
- Sale Overview: On January 22, 2026, Fairmount Funds Management LLC indirectly sold 3.5 million shares of Cogent at $36.40 per share, generating approximately $127.4 million in transaction value, which represented 38.87% of its total indirect holdings, reducing its stake from 9,003,418 to 5,503,418 shares.
- Stock Surge Context: Cogent's stock skyrocketed over 342% in 2025, and this significant share sale has sparked speculation about management taking profits, although Fairmount's exact motives remain unclear; nonetheless, the over $120 million gain from this transaction is substantial.
- Holding Structure Analysis: Despite the large sale of common shares, Fairmount still holds approximately 67,414 units of Series A Convertible Preferred Stock, which could convert to about 16.85 million common shares, but due to a 9.9% ownership limit, they would need to sell some common shares first to facilitate this conversion.
- Investment Strategy and Market Performance: Fairmount Funds focuses heavily on biotech investments, with Cogent being a key part of its portfolio, showcasing potential in targeted therapies for rare diseases, and combined with its strong market performance, it may present long-term profit opportunities for investors.
See More
Fairmount Funds Sells 3.5 Million Shares of Cogent Biosciences
- Transaction Overview: On January 22, 2026, Fairmount Funds Management LLC indirectly sold 3.5 million shares of Cogent Biosciences for approximately $127.4 million, highlighting its investment strategy in the biotech sector.
- Change in Holdings: This transaction reduced Fairmount's indirect holdings by 38.87%, leaving 5,503,418 shares, which may indicate a potential shift in confidence regarding Cogent's future prospects.
- Market Context Analysis: At the time of the sale, Cogent's shares were priced at $36.40, lower than the closing price of $39.53 that day, suggesting a cautious market sentiment that could impact investor confidence.
- Investor Implications: Although Fairmount still holds about 67,414 units of Series A Convertible Preferred Stock, which could convert to approximately 16.85 million common shares, the 9.9% ownership limit will restrict future sales, affecting liquidity management.
See More
